Advertisement

Bioactive Poly(Arsenic) Compounds

Chapter
First Online:
Part of the Progress in Molecular and Subcellular Biology book series (PMSB, volume 54)

Abstract

An overview of the biological activities of arsenic compounds containing more than one arsenic atom in their molecular structure is presented. This contribution covers the literature of the last 10–12 years concerning the in vitro and in vivo studies on arsenic species. They include inorganic oxides and sulfides, already employed for a long time in traditional Chinese medicine and currently investigated against hematological or solid malignancies, with arsenic trioxide clinically used in the treatment of acute promyelocytic leukemia. Chemical and biological aspects on the marine product arsenicin A, representing the first and only organic polyarsenical isolated from Nature, have also been reviewed, pointing out the characterization of its C3H6As4O3 molecular structure by experimental and theoretical vibrational spectroscopies, the potent antimicrobial activities, and the promising perspectives as an antitumor agent.

Keywords

Acute Myeloid Leukemia Acute Promyelocytic Leukemia Arsenic Trioxide Arsenic Compound Acute Promyelocytic Leukemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

AML

Acute myeloid leukemia

APCI

Atmospheric pressure chemical ionization

APL

Acute promyelocytic leukemia

ATL

Adult T-cell leukemia

Bcl-xl

B-cell lymphoma-extra large

CML

Chronic myelogenous leukemia

DFT

Density functional theory

EI

Electron impact

FDA

Food and drug administration

Hh

Hedgehog

HTLV-I

Human T-cell leukemia virus type I

HPV

Human papillomavirus

IR

Infrared

JNK

Jun N-terminal kinase

MS

Mass spectrometry

NMR

Nuclear magnetic resonance

PML

Promyelocytic leukemia

RAR

Retinoic acid receptor

ROS

Reactive oxygen species

SAR

Structure-activity relationship

SDS

Sodium dodecyl sulfate

SUMO

Small ubiquitin-like modifier

SUV

Small unilamellar vesicles

TLC

Thin layer chromatography

UV

Ultraviolet

This is a preview of subscription content, log in to check access.

References

  1. Ahn WS, Bae SM, Lee KH, Kim YW, Lee JM, Namkoong SE, Lee IP, Kim CK, Seo JS, Sin JI, Kim YW (2004) Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells. Oncol Rep 12:573–580PubMedGoogle Scholar
  2. Antman KH (2001) Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6:1–2. doi: 10.1634/theoncologist.6-suppl_2-1 PubMedCrossRefGoogle Scholar
  3. Arulmozhiraja S, Coote ML, Lu D, Salem G, Wild SB (2011) Origin of the unusual ultraviolet absorption of arsenicin A. J Phys Chem A 115:4530–4534. doi: 10.1021/jp200956b PubMedCrossRefGoogle Scholar
  4. Au W-Y, Kwong Y-L (2008) Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin 29:296–304. doi: 10.1111/j.1745-7254.2008.00771.x PubMedCrossRefGoogle Scholar
  5. Balaz P, Sedlak J (2010) Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a mini review). Toxins 2:1568–1581. doi: 10.3390/toxins2061568 PubMedCentralPubMedCrossRefGoogle Scholar
  6. Balaz P, Fabian M, Pastorek M, Cholujova D, Sedlak J (2009) Mechanochemical preparation and anticancer effect of realgar As4S4 nanoparticles. Mater Lett 63:1542–1544. doi: 10.1016/j.matlet.2009.04.008 DOI:10.1016/j.matlet.2009.04.008#doilink CrossRefGoogle Scholar
  7. Binet F, Antoine F, Girard D (2009) Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin. Inflamm Allergy Drug Targets 8:21–27, http://dx.doi.org/10.2174/187152809787582516 PubMedCrossRefGoogle Scholar
  8. Chang HS, Bae SM, Kim YW, Kwak SY, Min HJ, Bae IJ, Lee YJ, Shin JC, Kim CK, Ahn WS (2007) Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: relation to the apoptosis molecular pathway. Int J Oncol 30:1129–1135PubMedGoogle Scholar
  9. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY (2001) Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol 38:26–36. doi: 10.1016/S0037-1963(01)90003-4 DOI:10.1016/S0037-1963%2801%2990003-4#doilink PubMedCrossRefGoogle Scholar
  10. Chou W-C, Dang CV (2005) Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol 12:1–6. doi: 10.1097/01.moh.0000148552.93303.45 PubMedCrossRefGoogle Scholar
  11. Chung WH, Sung BH, Kim SS, Rhim H, Kuh HJ (2009) Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int J Oncol 34:1669–1679. doi: 10.3892/ijo_00000298 PubMedGoogle Scholar
  12. Coe E, Schimmer AD (2008) Catalase activity and arsenic sensitivity in acute leukemia. Leuk Lymphoma 49:1976–1981. doi: 10.1080/10428190802353617 PubMedCrossRefGoogle Scholar
  13. Cotton FA, Wilkinson G (1988) Advanced inorganic chemistry, vol 5. Wiley, New York, NYGoogle Scholar
  14. Cui L, Newcombe C, Urgast DS, Raab A, Krupp EM, Feldmann J (2011) Assessing the toxicity of arsenic-bearing sulfide minerals with the bio-indicator Corophium volutator. Environ Chem 8:52–61. doi: 10.1071/EN10044 CrossRefGoogle Scholar
  15. Ellermann J, Lietz M, Merbach P, Thiele G, Zoubek G (1979) Chemie polyfunktioneller liganden,53Uber methyl-substituierte triarsa-trioxa-, triarsa-trithia-und triarsa-triaza-adamantane and űber den stark aufgeweiteten adamatan-käfig im schweel-derivat. Z Naturforsch 84b:975–982Google Scholar
  16. Emadi A, Gore SD (2010) Arsenic trioxide—an old drug rediscovered. Blood Rev 24:191–199. doi: 10.1016/j.blre.2010.04.001 DOI:10.1016/j.blre.2010.04.001#doilink PubMedCentralPubMedCrossRefGoogle Scholar
  17. Evens AM, Tallman MS, Gartenhaus RB (2004) The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 28:891–900PubMedCrossRefGoogle Scholar
  18. Francesconi KA, Kuehnelt D (2002) Arsenic compounds in the environment. In: Frankenberger WT Jr (ed) Environmental chemistry of arsenic. Dekker, New York, NYGoogle Scholar
  19. Fu Z-C, Zhang B, Fu Z-J (2010) As2O3 may be a treatment option for adenoid cystic carcinoma of salivary gland. Med Hypotheses 75:490–491. doi: 10.1016/j.mehy.2010.07.001 DOI:10.1016/j.mehy.2010.07.001#doilink PubMedCrossRefGoogle Scholar
  20. Gensini GF, Conti AA, Lippi D (2007) The contributions of Paul Ehrlich to infectious disease. J Infect 54:221–224. doi: 10.1016/j.jinf.2004.05.022 PubMedCrossRefGoogle Scholar
  21. Guella G, Mancini I, Mariotto G, Rossi B, Viliani G (2009) Vibrational analysis as a powerful tool in structure elucidation of polyarsenicals: a DFT-based investigation of arsenicin A. Phys Chem Chem Phys 11:2420–2427. doi: 10.1039/b816729j PubMedCrossRefGoogle Scholar
  22. Hussein MA (2001) Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma. Med Oncol 18:239–242, http://dx.doi.org/10.1385/MO:18:4:239 PubMedCrossRefGoogle Scholar
  23. Ishitsuka K, Hanada S, Uozumi K, Utsunomiya A, Arima T (2000) Arsenic trioxide and the growth of human T- cell leukemia virus type I infected T- cell lines. Leuk Lymphoma 37:649–655. doi: 10.3109/10428190009058521 PubMedCrossRefGoogle Scholar
  24. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigna DE, Teruya-Felstein J, Pandolfi PP (2008) PML targeting eradicated quiescent leukaemia-initiating cells. Nature 453:1072–1078. doi: 10.1038/nature07016 PubMedCentralPubMedCrossRefGoogle Scholar
  25. Jing Y, Waxman S (2007) The design of selective and non-selective combination therapy for acute promyelocytic leukemia. Curr Top Microbiol Immunol 313:245–269. doi: 10.1007/978-3-540-34594-7_13 PubMedGoogle Scholar
  26. Khan MAS, Oubrahim H, Stadtman ER (2004) Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome. Proc Natl Acad Sci USA 101:11560–11565. doi: 10.1073/pnas.0404101101 PubMedCrossRefGoogle Scholar
  27. Kim J, Lee JJ, Kim J, Grdner D, Beachy PA (2007) Arsenic antagonizes the hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA 107:13432–13437. doi: 10.1073/pnas.1006822107 CrossRefGoogle Scholar
  28. Lin M, Wang Z, Zhang D (2007) Preparation of orpiment nanoparticles and their cytotoxic effect on cultured leukemia K562 cells. J Nanosci Nanotechnol 7:490–496. doi: 10.1166/jnn.2007.145 PubMedCrossRefGoogle Scholar
  29. Liu J, Lu Y, Wu Q, Goyer RA, Waalkes MP (2008) Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther 326:363–368. doi: 10.1124/jpet.108.139543 PubMedCentralPubMedCrossRefGoogle Scholar
  30. Lloyd NC, Morgan HW, Nicholson BK, Ronimus RS (2005) The composition of Ehrlich’s Salvarsan: resolution of a century-old debate. Angew Chem Int Ed 44:941–944. doi: 10.1002/anie.200461471 CrossRefGoogle Scholar
  31. Lu D-P, Wang Q (2002) Current study of APL treatment in China. Int J Hematol 76:316–318PubMedCrossRefGoogle Scholar
  32. Lu D, Rae AD, Salem G, Weir ML, Willis AC, Wild SB (2010) Arsenicin A, a natural polyarsenical: synthesis and crystal structure. Organometallics 29:32–33. doi: 10.1021/om90098q CrossRefGoogle Scholar
  33. Lu Y-F, Wu Q, Yan J-W, Shi J-Z, Liu J, Shi J-S (2011) Realgar, cinnabar and An-Gong-Niu-Huang Wan are much less chronically nephrotoxic than common arsenicals and mercurial. Exp Biol Med 236:233–239. doi: 10.1016/j.cbi.2010.11.006 CrossRefGoogle Scholar
  34. Mancini I, Guella G, Frostin M, Hnawia E, Laurent D, Debitus C, Pietra F (2006) On the first polyarsenic organic compound from nature: arsenicin A from the New Caledonian marine sponge Echinochalina bargibanti. Chem Eur J 12:8989–8994. doi: 10.1002/chem.200600783 PubMedCrossRefGoogle Scholar
  35. Mancini I, Defant A, Guella G (2007) Recent synthesis of marine natural products with antibacterial activities. AntiInfect Agents Med Chem 6:17–48. doi: 10.1080/00397910802044249 CrossRefGoogle Scholar
  36. Mann KK, Miller WH Jr (2004) Death by arsenic: implications of PML sumoylation. Cancer Cell 5:307–309, http://dx.doi.org/ 10.1016/S1535-6108(04)00089-3 PubMedCrossRefGoogle Scholar
  37. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62:3893–3903, http://cancerres.aacrjournals.org/content/62/14/3893.full PubMedGoogle Scholar
  38. Moe B, Chen B, Li XF, Le C (2010) Profiling the cytotoxicity of a novel polyarsenical in human carcinoma cell lines. Presented at the Faculty Research and Development Day Program, University of Alberta Canada, November 19th, 2010 Abstracts page17, http://www.pharm.ualberta.ca/~/media/University%20of%20Alberta/Faculties/Phacy%20and%20Pharmaceutical%20Sciences/Faculty%20Site/Research/Research%20Day/2010%20Research%20Day/BrochureResearch_Day_2010_3.pdf
  39. Munir ZA, Street GB, Winters HF (1971) Mass-spectrometric and vapor pressure studies on the sublimation of realgar (As4S4). J Chem Phys 55:4520–4527CrossRefGoogle Scholar
  40. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi PP, Rochette-Egly C, Zhu J, de Thé H (2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 14:1333–1342. doi: 10.1038/nm.1891 PubMedCrossRefGoogle Scholar
  41. O’Day PA (2006) Chemistry and mineralogy of arsenic. Elements 2:77–83. doi: 10.2113/gselements.2.2.77 CrossRefGoogle Scholar
  42. Pagliai M, Bonazzi P, Bindi L, Muniz-Miranda M, Cardini G (2011) Structural and vibrational properties of arsenic sulfides: alacranite (As8S9). J Phys Chem A 115:4558–4562. doi: 10.1021/jp201097k PubMedCrossRefGoogle Scholar
  43. Park MJ, Park IC, Bae IJ, Seo KM, Lee SH, Hong SI, Eun CK, Zhang W, Rhee CH (2003a) Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. Int J Oncol 22:1271–1276PubMedGoogle Scholar
  44. Park IC, Park MJ, Woo SH, Lee HC, An S, Gwak HS, Lee SH, Hong SI, Bae IJ, Seo KM, Rhee CH (2003b) Tetraarsenic oxide induces apoptosis in U937 leukemic cells through a reactive oxygen species-dependent pathway. Int J Oncol 23:943–948PubMedGoogle Scholar
  45. Park SG, Jung JJ, Won HJ, Kang MS, Seo SK, Choi IW, Eun CK, Ahn KJ, Park CW, Lee SW, Lew YS, Bae IJ, Choi IH (2009) Tetra-arsenic oxide (tetras) enhances radiation sensitivity of solid tumors by anti-vascular effect. Cancer Lett 277:212–217. doi: 10.1016/j.canlet.2008.12.012 PubMedCrossRefGoogle Scholar
  46. Platanias LC, Robert H (2009) Biological responses to arsenic compounds. J Biol Chem 284:18583–18587. doi: 10.1074/jbc.R900003200 PubMedCrossRefGoogle Scholar
  47. Qi J, He P, Chen W, Wang H, Wang X, Zhang M (2010) Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells. Leuk Res 34:1506–1516. doi: 10.1016/j.leukres.2010.03.038 PubMedCrossRefGoogle Scholar
  48. Ramadan D, Rancy PC, Nagarkar RP, Schneider JP, Thorpe C (2009) Arsenic (III) species inhibit oxidative protein folding in vitro. Biochemistry 48:424–432. doi: 10.1021/bi801988x PubMedCentralPubMedCrossRefGoogle Scholar
  49. Richardson PG, Mitsiades CS, Hideshima T, Anderson KC (2005) Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Hematol 18:619–634, http://dx.doi.org/ 10.1016/j.beha.2005.01.01 CrossRefGoogle Scholar
  50. Sanchez Y, Amran D, de Blas E, Aller P (2010) Arsenic trioxide as an anti-tumour agent: mechanisms of action and strategies of sensitization. J Appl Biomed 8:199–208. doi: 10.2478/v10136-009-0027-3 CrossRefGoogle Scholar
  51. Shen Z-X, Shi Z-Z, Fang J, Gu B-W, Li J-M, Zhu Y-M, Shi J-Y, Zheng P-Z, Yan H, Liu Y-F, Chen Y, Shen Y, Wu W, Tang W, Waxman S, de Thé H, Wang Z-Y, Chen S-J, Chen Z (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101:5328–5335. doi: 10.1073/pnas.0400053101 PubMedCrossRefGoogle Scholar
  52. Shen XC, Jin T, Xie J, Liang H, Yan Y (2009) Studies on the biomimetic membrane interaction between liposome and realgar nanoparticles. Sci China B 52:1512–1518. doi: 10.1007/s11426-009-0223-8 CrossRefGoogle Scholar
  53. Singh P, Sharma R (1994) Effect of orpiment (As2S3) on cytochrome P 450, glutathione and lipid peroxide levels of rat liver. J Environ Pathol Toxicol Oncol 13:199–203PubMedGoogle Scholar
  54. Singh P, Sharma R (1998) In vivo effects of orpiment administration on the lipid profile of rat lungs. Pollut Res 17:307–310Google Scholar
  55. Singh P, Gregory MA, Sharma R, Kiran R (1999) Effects of orpiment (As2S3) toxicity on the kinetic and thermodynamic parameters of some brush-border membrane enzymes of rat intestine. Pollut Res 18:75–78Google Scholar
  56. Tähtineen P, Saielli G, Mancini I, Bagno A (2008) Computational NMR spectroscopy of organoarsenicals and the natural polyarsenic compound arsenicin A. Chem Eur J 14:10445–10452. doi: 10.1002/chem.200801272 CrossRefGoogle Scholar
  57. Tang Y, Wang N, Zhang Y, Ye S, Ou W (2008) Effects of realgar on stress proteins, inflammatory mediators, and complement in brain tissue and serum of rats with inflammatory brain injury. Neural Regen Res 3:885–889Google Scholar
  58. Wang ZY (2001) Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 48:S72–S76. doi: 10.1007/s002800100309 PubMedCrossRefGoogle Scholar
  59. Wang J, Lin M, Zhang T, Yan Y, Ho PC, Xu QH, Loh KP (2008a) Arsenic(II) sulfide quantum dots prepared by a wet process from its bulk. J Am Chem Soc 130:11596–11597. doi: 10.1021/ia804436w PubMedCrossRefGoogle Scholar
  60. Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ, Chen Z (2008b) Dissection of mechanisms of Chinese medicinal formula realgar-indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 105:4826–4831. doi: 10.1073/pnas.0712365105 PubMedCrossRefGoogle Scholar
  61. Wang LW, Shi YL, Wang N, Gou BD, Zhang TL, Wang K (2009) Association of oxidative stress with realgar-induced differentiation in human leukemia HL-60 cells. Chemotherapy 55:460–467. doi: 10.1159/000265528 PubMedCrossRefGoogle Scholar
  62. Wang Y, Wu JIC, Li Q, von Ragué Schleyer P (2010) Why are some (CH)4X6 and (CH2)6X4 polyheteroadamantanes so stable? Org Lett 12:1320–1323. doi: 10.1021/ol1002187 PubMedCrossRefGoogle Scholar
  63. Waxman S, Anderson KC (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6:3–10. doi: 10.1634/theoncologist.6-suppl_2-3 PubMedCrossRefGoogle Scholar
  64. Wei L, Liao P, Wu H, Li X, Pei F, Li W, Wu Y (2009) Metabolic profiling studies on the toxicological effects of realgar in rats by 1H NMR spectroscopy. Toxicol Appl Pharmacol 234:314–325. doi: 10.1016/j.taap.2008.11.010 PubMedCrossRefGoogle Scholar
  65. Woo SH, Park MJ, An S, Lee HC, Jin HO, Lee SJ, Gwak HS, Park IC, Hong SI, Rhee CH (2005) Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced proliferation of human endothelial cells. J Cell Biochem 95:120–130. doi: 10.1002/jcb.20329 PubMedCrossRefGoogle Scholar
  66. Wu JZ, Ho PC (2006) Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur J Pharm Sci 29:35–44. doi: 10.1016/j.ejps.2006.05.002 PubMedCrossRefGoogle Scholar
  67. Wu J-Z, Ho PC (2009) Comparing the relative oxidative DNA damage caused by various arsenic species by quantifying urinary levels of 8-hydroxy-2′-deoxyguanosine with isotope-dilution liquid chromatography/mass spectrometry. Pharm Res 26:1525–1533. doi: 10.1007/s11095-009-9865-7 PubMedCrossRefGoogle Scholar
  68. Wu JZ, Shao YB, Liu JL, Chen G, Ho PC (2011) The medicinal use of realgar (As4S4) and its recent development as an anticancer agent. J Ethnopharmacol 135:595–602. doi: 10.1016/j.jep.2011.03.071 PubMedCrossRefGoogle Scholar
  69. Xu L, Zeng F, Ye H, Yang X, Xu H (2006) Anti-tumor activity of realgar nanoparticles and the distribution of arsenic (As) in tissues of tumor-transplanted mice. Zhongguo Xinyao Zazhi 15:1845–1848, CNKI:SUN:ZXYZ.0.2006-21-013Google Scholar
  70. Yoo MH, Kim JT, Rhee CH, Park MJ, Bae IJ, Yi NY, Jeong MB, Jeong SM, Nam TC, Seo KM (2004) Reverse effects of tetraarsenic oxide on the angiogenesis induced by nerve growth factor in the rat cornea. J Vet Med Sci 66:1091–1095. doi: 10.1292/jvms.66.1091 PubMedCrossRefGoogle Scholar
  71. Zhang C, Ling C (2003) Review of arsenic trioxide effect on solid cancer. Acad J Second Mil Med Univ 24:440–443, cnki:ISSN:0258-879X.0.2003-04-032Google Scholar
  72. Zhang J, Wang JC, Han YH, Wang LF, Ji SP, Liu SX, Liu XP, Yao LB (2005) High expression of bcl-xL in K562 cells and its role in the low sensitivity of K562 to realgar-induced apoptosis. Acta Haematol 113:247–254. doi: 10.1159/000084678 PubMedCrossRefGoogle Scholar
  73. Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, Weng L, Zhang Y, Chen Q, Chen SJ, Chen Z (2009) A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci USA 106:3378–3383. doi: 10.1073/pnas.0813142106 PubMedCrossRefGoogle Scholar
  74. Zhang X, Xie Q, Wang X, Wang B, Li H (2010a) Biological extraction of realgar by and its in vitro and in vivo antitumor activities. Pharm Biol 48:40–47. doi: 10.3109/13880200903029381 PubMedCrossRefGoogle Scholar
  75. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z (2010b) Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science 328:240–243. doi: 10.1126/science.1183424 PubMedCrossRefGoogle Scholar
  76. Zhao W, Lu X, Yuan Y, Liu C, Yang B, Hong H, Wang G, Zeng F (2011) Effect of size and processing method on the cytotoxicity of realgar nanoparticles in cancer cell lines. Int J Nanomedicine 6:1569–1577. doi: 10.2147/IJN.S21373 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Laboratorio di Chimica Bioorganica, Dipartimento di FisicaUniversità di TrentoPovo-TrentoItaly

Personalised recommendations

Cite chapter

Buy options